BALAXI
Balaxi Pharmaceuticals Limited (NSE: Balaxi) Q2 & H1 FY27: Revenue Up 39%, PAT Surges 450%
Balaxi Pharmaceuticals Limited (NSE: BALAXI) reports strong Q2 & H1 FY27 results with revenue up 39% and PAT surging 450%.
Balaxi Pharmaceuticals Limited (NSE: BALAXI) continues to demonstrate robust growth in its branded, IPR-driven business model, particularly in frontier markets. In the first half of FY27, the company reported a 39% increase in revenue and a staggering 450% surge in PAT compared to the same period last year.
Strong Revenue Growth
The company’s total revenue for H1 FY27 stood at ₹16,023.35 crore, up from ₹12,672.58 crore in H1 FY26. This impressive growth is driven by Balaxi’s strategic focus on expanding its product portfolio and enhancing market presence in Africa and Latin America.
Profitability Boost
Profit After Tax (PAT) for H1 FY27 was ₹244.76 crore, a significant increase from ₹49.91 crore in H1 FY26. The PAT margin also improved from 0.39% to 1.53%. Earnings Per Share (EPS) surged from ₹0.09 to ₹0.44, reflecting the company’s strong financial performance.
Strategic Expansion
Balaxi Pharmaceuticals has added 37 new product registrations in H1 FY27, bringing the total to over 1,000 registered products. The company’s manufacturing facility in Jadcherla, Telangana, is ramping up commercial production, which is expected to capture margins previously paid to contract manufacturers and open new market opportunities.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of BALAXI PHARMACEUTICALS LIMITED
BALAXI PHARMACEUTICALS LIMITED belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
BALAXI moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue contracts at -7.1% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 5.7% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at -7.1% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of BALAXI PHARMACEUTICALS LIMITED.
-
Financial Services2 days agoSammaan Capital Limited (sammaancap) Q2 FY27: Disbursements Rise 62% Qoq and PAT Grows 28%
-
Consumer Cyclical2 days agoSenco Gold Limited (senco) Investor Presentation Q2 & H1 FY27 Highlights
-
Healthcare2 days agoZydus Lifesciences Limited (zyduslife) Inspection by USFDA Concludes at Liqmeds, UK
-
Capital Markets2 days agoMaster Trust Limited (mastertr): Mastercapitalservices Raises ₹75 Cr Through Ncds
-
Financial Services2 days agoSammaan Capital Limited (sammaancap) Q2fy27 Investor Presentation: Strong Growth and Expansion
-
Communication Equipment2 days agoTamilnadu Telecommunication Limited (tntele) Reports Q2 FY27: Net Loss Deepens
-
Solar2 days agoSolex Energy Limited (solex) Q2 FY27 Results: Revenue Up 75.8%, Orders Surge
-
Basic Materials2 days agoGalaxy Surfactants Limited (galaxysurf) Signs Mou with LG Electronics for Sustainable Cleaning Solutions
